PL3670499T3 - Pochodne pirazolu użyteczne jako inhibitory białka aktywującego 5-lipooksygenazę (FLAP) - Google Patents
Pochodne pirazolu użyteczne jako inhibitory białka aktywującego 5-lipooksygenazę (FLAP)Info
- Publication number
- PL3670499T3 PL3670499T3 PL19199606T PL19199606T PL3670499T3 PL 3670499 T3 PL3670499 T3 PL 3670499T3 PL 19199606 T PL19199606 T PL 19199606T PL 19199606 T PL19199606 T PL 19199606T PL 3670499 T3 PL3670499 T3 PL 3670499T3
- Authority
- PL
- Poland
- Prior art keywords
- flap
- inhibitors
- activating protein
- pyrazole derivatives
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156424P | 2015-05-04 | 2015-05-04 | |
| PCT/EP2016/059848 WO2016177703A1 (en) | 2015-05-04 | 2016-05-03 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors |
| EP16720116.9A EP3292105B1 (en) | 2015-05-04 | 2016-05-03 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors |
| EP19199606.5A EP3670499B1 (en) | 2015-05-04 | 2016-05-03 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3670499T3 true PL3670499T3 (pl) | 2022-02-14 |
Family
ID=55910253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19199606T PL3670499T3 (pl) | 2015-05-04 | 2016-05-03 | Pochodne pirazolu użyteczne jako inhibitory białka aktywującego 5-lipooksygenazę (FLAP) |
| PL16720116T PL3292105T3 (pl) | 2015-05-04 | 2016-05-03 | Pochodne pirazolu użyteczne jako inhibitory białka aktywującego 5-lipooksygenazę (flap) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16720116T PL3292105T3 (pl) | 2015-05-04 | 2016-05-03 | Pochodne pirazolu użyteczne jako inhibitory białka aktywującego 5-lipooksygenazę (flap) |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US10183947B2 (pl) |
| EP (2) | EP3292105B1 (pl) |
| JP (1) | JP6564062B2 (pl) |
| KR (1) | KR102623474B1 (pl) |
| CN (1) | CN107646036B (pl) |
| AR (1) | AR104512A1 (pl) |
| AU (1) | AU2016258874B2 (pl) |
| BR (1) | BR112017022757B1 (pl) |
| CA (1) | CA2983668C (pl) |
| CL (1) | CL2017002660A1 (pl) |
| CO (1) | CO2017011506A2 (pl) |
| CR (1) | CR20170513A (pl) |
| CY (2) | CY1122689T1 (pl) |
| DK (2) | DK3292105T3 (pl) |
| DO (1) | DOP2017000244A (pl) |
| EA (1) | EA032221B1 (pl) |
| ES (2) | ES2902139T3 (pl) |
| GT (1) | GT201700220A (pl) |
| HK (1) | HK1245255A1 (pl) |
| HR (2) | HRP20211993T1 (pl) |
| HU (2) | HUE047445T2 (pl) |
| IL (1) | IL255069B (pl) |
| LT (1) | LT3670499T (pl) |
| ME (1) | ME03663B (pl) |
| MX (1) | MX2017013571A (pl) |
| MY (1) | MY186647A (pl) |
| PE (1) | PE20180247A1 (pl) |
| PH (1) | PH12017502112B1 (pl) |
| PL (2) | PL3670499T3 (pl) |
| PT (2) | PT3670499T (pl) |
| RS (2) | RS59671B1 (pl) |
| SG (1) | SG11201708558RA (pl) |
| SI (2) | SI3292105T1 (pl) |
| SV (1) | SV2017005549A (pl) |
| TN (1) | TN2017000458A1 (pl) |
| TW (1) | TWI718146B (pl) |
| WO (1) | WO2016177703A1 (pl) |
| ZA (1) | ZA201708189B (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3292105T1 (sl) * | 2015-05-04 | 2020-01-31 | Astrazeneca Ab | Derivati pirazola uporabni kot inhibitorji proteina, ki aktivira 5-lipoksigenazo (FLAP) |
| CA3040341C (en) | 2016-10-28 | 2024-03-05 | Astrazeneca Ab | Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide |
| CN110169969B (zh) * | 2019-06-28 | 2022-05-27 | 南京医科大学 | Mk571在制备预防和治疗心脏病药物中应用 |
| CN111084775A (zh) * | 2020-02-17 | 2020-05-01 | 牡丹江医学院 | 一种用于治疗癫痫的药物组合物 |
| CN111419800B (zh) * | 2020-04-23 | 2021-03-19 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 用于治疗红斑狼疮的药物制剂及其制备方法 |
| CN111643498B (zh) * | 2020-07-20 | 2021-05-07 | 黑龙江中医药大学 | 一种治疗肾结石的药物组合物及其用途 |
| CN111714499B (zh) * | 2020-07-27 | 2021-05-11 | 黑龙江中医药大学 | 一种用于治疗多囊卵巢综合征的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP9400632A0 (en) | 1993-04-29 | 1995-10-07 | Zeneca Ltd | Ether derivatives. |
| US5773422A (en) | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
| CA2572750A1 (en) * | 2003-09-10 | 2005-03-17 | Anil Koul | Heterobicyclic compounds as pharmaceutically active agents |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| TW200815351A (en) * | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| US20100204282A1 (en) | 2007-02-05 | 2010-08-12 | Hutchinson John H | Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| MX2009011357A (es) * | 2007-04-20 | 2009-11-05 | Schering Corp | Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos. |
| NZ580801A (en) * | 2007-05-10 | 2012-09-28 | Bristol Myers Squibb Co | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP2207547A4 (en) | 2007-10-05 | 2010-11-17 | Amira Pharmaceuticals Inc | PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE |
| SI3292105T1 (sl) * | 2015-05-04 | 2020-01-31 | Astrazeneca Ab | Derivati pirazola uporabni kot inhibitorji proteina, ki aktivira 5-lipoksigenazo (FLAP) |
-
2016
- 2016-05-03 SI SI201630537T patent/SI3292105T1/sl unknown
- 2016-05-03 TW TW105113757A patent/TWI718146B/zh active
- 2016-05-03 RS RS20191604A patent/RS59671B1/sr unknown
- 2016-05-03 EA EA201792341A patent/EA032221B1/ru not_active IP Right Cessation
- 2016-05-03 MX MX2017013571A patent/MX2017013571A/es active IP Right Grant
- 2016-05-03 PL PL19199606T patent/PL3670499T3/pl unknown
- 2016-05-03 HU HUE16720116A patent/HUE047445T2/hu unknown
- 2016-05-03 PT PT191996065T patent/PT3670499T/pt unknown
- 2016-05-03 AR ARP160101257A patent/AR104512A1/es active IP Right Grant
- 2016-05-03 PE PE2017002308A patent/PE20180247A1/es unknown
- 2016-05-03 DK DK16720116T patent/DK3292105T3/da active
- 2016-05-03 EP EP16720116.9A patent/EP3292105B1/en active Active
- 2016-05-03 PT PT167201169T patent/PT3292105T/pt unknown
- 2016-05-03 HR HRP20211993TT patent/HRP20211993T1/hr unknown
- 2016-05-03 CA CA2983668A patent/CA2983668C/en active Active
- 2016-05-03 TN TNP/2017/000458A patent/TN2017000458A1/en unknown
- 2016-05-03 BR BR112017022757-6A patent/BR112017022757B1/pt active IP Right Grant
- 2016-05-03 HU HUE19199606A patent/HUE056875T2/hu unknown
- 2016-05-03 ME MEP-2019-358A patent/ME03663B/me unknown
- 2016-05-03 MY MYPI2017704101A patent/MY186647A/en unknown
- 2016-05-03 CR CR20170513A patent/CR20170513A/es unknown
- 2016-05-03 SG SG11201708558RA patent/SG11201708558RA/en unknown
- 2016-05-03 LT LTEP19199606.5T patent/LT3670499T/lt unknown
- 2016-05-03 WO PCT/EP2016/059848 patent/WO2016177703A1/en active Application Filing
- 2016-05-03 JP JP2017555792A patent/JP6564062B2/ja active Active
- 2016-05-03 PL PL16720116T patent/PL3292105T3/pl unknown
- 2016-05-03 DK DK19199606.5T patent/DK3670499T3/da active
- 2016-05-03 US US15/571,291 patent/US10183947B2/en active Active
- 2016-05-03 KR KR1020177034920A patent/KR102623474B1/ko active IP Right Grant
- 2016-05-03 ES ES19199606T patent/ES2902139T3/es active Active
- 2016-05-03 CN CN201680029387.0A patent/CN107646036B/zh active Active
- 2016-05-03 SI SI201631428T patent/SI3670499T1/sl unknown
- 2016-05-03 RS RS20211559A patent/RS62729B1/sr unknown
- 2016-05-03 ES ES16720116T patent/ES2760466T3/es active Active
- 2016-05-03 EP EP19199606.5A patent/EP3670499B1/en active Active
- 2016-05-03 AU AU2016258874A patent/AU2016258874B2/en active Active
-
2017
- 2017-10-16 IL IL255069A patent/IL255069B/en active IP Right Grant
- 2017-10-18 GT GT201700220A patent/GT201700220A/es unknown
- 2017-10-19 CL CL2017002660A patent/CL2017002660A1/es unknown
- 2017-10-20 DO DO2017000244A patent/DOP2017000244A/es unknown
- 2017-10-20 SV SV2017005549A patent/SV2017005549A/es unknown
- 2017-11-09 CO CONC2017/0011506A patent/CO2017011506A2/es unknown
- 2017-11-21 PH PH12017502112A patent/PH12017502112B1/en unknown
- 2017-12-01 ZA ZA2017/08189A patent/ZA201708189B/en unknown
-
2018
- 2018-04-06 HK HK18104539.0A patent/HK1245255A1/zh unknown
- 2018-11-20 US US16/196,217 patent/US10508119B2/en active Active
-
2019
- 2019-10-30 US US16/668,743 patent/US11001589B2/en active Active
- 2019-12-02 HR HRP20192172TT patent/HRP20192172T1/hr unknown
- 2019-12-03 CY CY20191101268T patent/CY1122689T1/el unknown
-
2021
- 2021-04-22 US US17/237,656 patent/US11691978B2/en active Active
- 2021-12-23 CY CY20211101130T patent/CY1125179T1/el unknown
-
2023
- 2023-02-27 US US18/174,832 patent/US20230219967A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267343A (en) | Pyrazole history as malt1 inhibitors | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| EP3166608A4 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| HK1245255A1 (zh) | 作爲5-脂氧合酶激活蛋白(flap)抑制劑有用的吡唑衍生物 | |
| EP3149008B8 (en) | Certain protein kinase inhibitors | |
| IL251777A0 (en) | New pyrazole histories as nik inhibitors | |
| HRP20190127T1 (hr) | Derivati pirolidinona kao inhibitori metap-2 | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| EP3256450A4 (en) | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof | |
| EP3186247A4 (en) | Protein kinase inhibitors | |
| EP3224248A4 (en) | Certain protein kinase inhibitors | |
| EP3383877A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| IL247220A0 (en) | Amino pyrazoline derivatives, preparations containing them and their uses | |
| EP3312172A4 (en) | aminopyrazole | |
| EP3400220A4 (en) | PYRAZOLE DERIVATIVES | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors |